Please Scroll Down to See Forums Below
napsgear
genezapharmateuticals
domestic-supply
puritysourcelabs
UGL OZ
UGFREAK
napsgeargenezapharmateuticals domestic-supplypuritysourcelabsUGL OZUGFREAK

My assault on Nolvadex!! (Nolva is a carcinogen??)

AlwaysOn

New member
Nolvadex is a Class I Carcinogen





Breast J. 2002 Mar-Apr;8(2):92-6. Related Articles, Links


Toxicity of antiestrogens.

Hirsimaki P, Aaltonen A, Mantyla E.

Department of Pathology, Turku University Central Hospital, BioCity, Tykistokatu B.8.6., FIN-20520 Turku, Finland. [email protected]

The object of this article is to review briefly the preclinical and clinical safety of some antiestrogens. Tamoxifen, toremifene, droloxifene, and idoxifene are polyphenylethylene antiestrogens, whereas the pure antiestrogen, ICI 182,780 or faslodex, as well as raloxifene, is of a different structure. Tamoxifen has been shown to be genotoxic in several studies. It induces unscheduled DNA synthesis in rat hepatocytes and micronuclei in MCL-5 a cells in vitro. Tamoxifen also induces aneuploidy in rat liver in vivo and chromosome aberrations and micronuclei in mouse bone marrow. Toremifene has also shown to be genotoxic, but to a far lower extent, by inducing micronuclei in MCL-5 a cells in vitro and by inducing aneuploidy in rat liver in vivo. Tamoxifen has been shown to be hepatocarcinogenic in the rat in at least four independent long-term studies. The initiation of tumors in the rat is the result of metabolic activation by cytochrome P450 isoenzymes to an electrophile(s) that binds irreversibly to DNA. The other antiestrogens have not been shown to be carcinogenic in rodents. In several independent clinical studies, the risk of endometrial cancer has increased among tamoxifen-treated women. After reviewing the available data, the International Agency for Research on Cancer concluded that there was sufficient evidence to show that tamoxifen is a class I human carcinogen. The increased risk for endometrial cancer occurs predominantly among women who are 50 years old or older and who have been treated with tamoxifen. It is not yet clear whether the uterine tumor formation is a result of genetic mechanisms, analogous to those seen in the rat liver or due to the estrogen agonist action of tamoxifen. However, the other antiestrogens with a more or less similar intrinsic estrogenic potential have not been shown to be carcinogenic in humans.

Publication Types:
Review
Review, Tutorial

PMID: 11896754 [PubMed - indexed for MEDLINE]
 
So what is the answer?

There is a tamoxifen derivative called toremifene. It has the same halogenated substitute that makes clomid less toxic, but with tamoxifen's structure. It's called Fareston by trade name.


There is another compound, raloxifene, that is sold under the name of Evista that is better at curing gyno than nolva (as proved in a study I don't have in front of me right now) and is better at preserving the GOOD effects of estrogen especially in bone.



I need help in choosing between these two. This is where you guys come in!!


Can someone post studies comparing these two in terms of genotoxicity and cholesterol levels?



thanks
 
Last edited:
AlwaysOn said:
The increased risk for endometrial cancer occurs predominantly among women who are 50 years old or older and who have been treated with tamoxifen.

Most of us aren't women 50 years old or older......

hmmm.....

hmm...

hm..

:idea:





DIV
 
bruce410 said:
yeah divisional changes are going to call for a study on men. haha

Some changes need to be made for the sake of science.....

Unfortunately.......Chynna Doll was not one of them. :worried:




DIV
 
Plus who can get that other stuff? I'd try it if I could get it. To tell you the truth, I've never even heard of it before.
 
Top Bottom